Safety of Perioperative Intravenous Different Doses of Dexamethasone in Primary Total Joint Arthroplasty: a Retrospective Large-scale Cohort Study

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Specialties Orthopedics
Physiology

Date 2024 Dec 26

PMID 39725995

Authors

Ping Mou

Xiao-Dan Zhao

Xiu-Mei Tang

Zun-Han Liu

Hao-Yang Wang

Wei-Nan Zeng

Duan Wang

Zong-Ke Zhou

Affiliations

Soon will be listed here.

Abstract

Purpose: Perioperative intravenous different doses of dexamethasone (DEX) can realize effective clinical outcomes in total joint arthroplasty (TJA). However, the effect of different DEX doses on readmission rates and postoperative complications remains unclear.

Methods: We retrospectively analyzed patients who underwent primary TJA between December 2012 and October 2020. Patients were categorized into three groups based on the total perioperative dose of DEX: control group (DEX = 0 mg), low-dose group (DEX < 15 mg), and high-dose group (DEX ≥ 15 mg). Primary outcomes included 30-day and 90-day readmission rates. Secondary outcomes included the rates of periprosthetic joint infection (PJI) and wound complications, with treatment outcomes for these complications were also evaluated. Multivariable analysis was used to identify risk factors for readmission.

Results: A total of 14,557 procedures were included, with 6,686 in the control group, 4,325 in the low-dose group, and 3,546 in the high-dose group. No significant differences were observed among the groups for 30-day (p = 0.645) or 90-day readmission rates (p = 0.539). Additionally, there were no significant differences in rates of PJI (p = 0.401) or wound complications (p = 0.079). Treatment for PJI and wound complications was successful across all groups. Risk factors for 30-day readmission included age > 80 years (OR: 2.585, 95% CI: 1.123-5.954, p = 0.026) and undergoing total hip arthroplasty (THA) (OR: 1.692, 95% CI: 1.137-2.518, p = 0.009). For 90-day readmission, age 71-80 years (OR: 2.199, 95% CI: 1.349-3.583, p = 0.002), age > 80 years (OR: 3.897, 95% CI: 1.966-7.727, p < 0.001), and THA (OR: 1.622, 95% CI: 1.179-2.230, p = 0.003) were significant risk factors. However, neither low-dose nor high-dose DEX was associated with increased 30-day or 90-day readmission rates.

Conclusions: Perioperative intravenous DEX may be not associated with the readmission, PJI, and wound complications in patients undergoing primary TJA.

References

Zmistowski B, Restrepo C, Hess J, Adibi D, Cangoz S, Parvizi J . Unplanned readmission after total joint arthroplasty: rates, reasons, and risk factors. J Bone Joint Surg Am. 2013; 95(20):1869-76. DOI: 10.2106/JBJS.L.00679. View

Salerno A, Hermann R . Efficacy and safety of steroid use for postoperative pain relief. Update and review of the medical literature. J Bone Joint Surg Am. 2006; 88(6):1361-72. DOI: 10.2106/JBJS.D.03018. View

Avram V, Petruccelli D, Winemaker M, de Beer J . Total joint arthroplasty readmission rates and reasons for 30-day hospital readmission. J Arthroplasty. 2013; 29(3):465-8. DOI: 10.1016/j.arth.2013.07.039. View

Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster C . Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016; 15(4):457-65. DOI: 10.1517/14740338.2016.1140743. View

Goltz D, Ryan S, Hopkins T, Howell C, Attarian D, Bolognesi M . A Novel Risk Calculator Predicts 90-Day Readmission Following Total Joint Arthroplasty. J Bone Joint Surg Am. 2019; 101(6):547-556. DOI: 10.2106/JBJS.18.00843. View

Gasbjerg K, Hagi-Pedersen D, Lunn T, Laursen C, Holmqvist M, Vinstrup L . Effect of dexamethasone as an analgesic adjuvant to multimodal pain treatment after total knee arthroplasty: randomised clinical trial. BMJ. 2022; 376:e067325. PMC: 8724786. DOI: 10.1136/bmj-2021-067325. View

Axon R, Williams M . Hospital readmission as an accountability measure. JAMA. 2011; 305(5):504-5. DOI: 10.1001/jama.2011.72. View

Lei Y, Huang Z, Huang Q, Pei F, Huang W . Is a split-dose intravenous dexamethasone regimen superior to a single high dose in reducing pain and improving function after total hip arthroplasty? A randomized blinded placebo-controlled trial. Bone Joint J. 2020; 102-B(11):1497-1504. DOI: 10.1302/0301-620X.102B11.BJJ-2020-1078.R1. View

Lex J, Edwards T, Packer T, Jones G, Ravi B . Perioperative Systemic Dexamethasone Reduces Length of Stay in Total Joint Arthroplasty: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Arthroplasty. 2020; 36(3):1168-1186. DOI: 10.1016/j.arth.2020.10.010. View

10.

Horan T, Gaynes R, Martone W, Jarvis W, Emori T . CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Am J Infect Control. 1992; 20(5):271-4. DOI: 10.1016/s0196-6553(05)80201-9. View

11.

Yu S, Garvin K, Healy W, Pellegrini Jr V, Iorio R . Preventing Hospital Readmissions and Limiting the Complications Associated With Total Joint Arthroplasty. Instr Course Lect. 2016; 65:199-210. View

12.

Richardson A, Bala A, Wellman S, Attarian D, Bolognesi M, Grant S . Perioperative Dexamethasone Administration Does Not Increase the Incidence of Postoperative Infection in Total Hip and Knee Arthroplasty: A Retrospective Analysis. J Arthroplasty. 2016; 31(8):1784-7. DOI: 10.1016/j.arth.2016.01.028. View

13.

Jorgensen C, Petersen M, Kehlet H . Preoperative prediction of potentially preventable morbidity after fast-track hip and knee arthroplasty: a detailed descriptive cohort study. BMJ Open. 2016; 6(1):e009813. PMC: 4716218. DOI: 10.1136/bmjopen-2015-009813. View

14.

Kocher R, Adashi E . Hospital readmissions and the Affordable Care Act: paying for coordinated quality care. JAMA. 2011; 306(16):1794-5. DOI: 10.1001/jama.2011.1561. View

15.

Lei Y, Huang Q, Xu B, Zhang S, Cao G, Pei F . Multiple Low-Dose Dexamethasone Further Improves Clinical Outcomes Following Total Hip Arthroplasty. J Arthroplasty. 2017; 33(5):1426-1431. DOI: 10.1016/j.arth.2017.11.057. View

16.

Jorgensen C, Pitter F, Kehlet H . Safety aspects of preoperative high-dose glucocorticoid in primary total knee replacement. Br J Anaesth. 2017; 119(2):267-275. DOI: 10.1093/bja/aex190. View

17.

Kurtz S, Lau E, Ong K, Adler E, Kolisek F, Manley M . Which Clinical and Patient Factors Influence the National Economic Burden of Hospital Readmissions After Total Joint Arthroplasty?. Clin Orthop Relat Res. 2017; 475(12):2926-2937. PMC: 5670047. DOI: 10.1007/s11999-017-5244-6. View

18.

Toner A, Ganeshanathan V, Chan M, Ho K, Corcoran T . Safety of Perioperative Glucocorticoids in Elective Noncardiac Surgery: A Systematic Review and Meta-analysis. Anesthesiology. 2016; 126(2):234-248. DOI: 10.1097/ALN.0000000000001466. View

19.

Xu H, Zhang S, Xie J, Lei Y, Cao G, Pei F . Multiple Doses of Perioperative Dexamethasone Further Improve Clinical Outcomes After Total Knee Arthroplasty: A Prospective, Randomized, Controlled Study. J Arthroplasty. 2018; 33(11):3448-3454. DOI: 10.1016/j.arth.2018.06.031. View

20.

Klement M, Wilkens H, Fillingham Y, Manrique J, Austin M, Parvizi J . Intraoperative Dexamethasone Reduces Readmission Rates Without Affecting Risk of Thromboembolic Events or Infection After Total Joint Arthroplasty. J Arthroplasty. 2018; 33(10):3252-3256. DOI: 10.1016/j.arth.2018.05.016. View